Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,821 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Therapeutics, Inc. Clear all
Terminated Phase 2 Interventional

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

NCT00662116
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
alagebrium, placebo
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 9, 2026, 5:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Obalon Navigation/Touch System Post-Approval Study

NCT04095481
View directory record Official record
Conditions
Obesity
Interventions
Obalon Navigation/Touch System
Device
Lead sponsor
Obalon Therapeutics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Flower Mound, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 9, 2026, 5:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

NCT06938711
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Onapristone
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Completed No phase listed Observational

The Evolution and Management of Migraine Recurrence Beyond 24 Hours

NCT00754611
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 9, 2026, 5:41 AM EDT
Withdrawn Phase 2 Interventional

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

NCT05284214
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult
Interventions
Sargramostim, Ipilimumab-containing therapy
Biological
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Results available

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

NCT03873987
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Current Formulation of Oritavancin, Kimyrsa
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Burr Ridge, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

NCT02109406
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD2115 Dose 1, AZD 2115, Dose 2, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Clearwater, Florida • Charleston, South Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

NCT06747273
View directory record Official record
Conditions
Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3
Interventions
SRP-9004
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Columbus, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated No phase listed Observational

Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

NCT05877066
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Greenwich, Connecticut • Temple Terrace, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections

NCT05599295
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infection
Interventions
Orbactiv, Kimyrsa
Drug
Lead sponsor
Melinta Therapeutics, LLC
Industry
Eligibility
3 Months to 11 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

NCT03802201
View directory record Official record
Conditions
β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia
Interventions
PTG-300
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Oakland, California • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 9, 2026, 5:41 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

NCT03351777
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PR022
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

NCT01566877
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-7288, Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

TGR1202 in Relapsed and Refractory Follicular Lymphoma

NCT03178201
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 9, 2026, 5:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

NCT01318226
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ATx08-001, Placebo
Drug
Lead sponsor
Aestus Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
9
States / cities
Chandler, Arizona • Peoria, Arizona • Cutler Bay (Miami), Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

NCT04125732
View directory record Official record
Conditions
Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases, Heart Diseases
Interventions
AdVEGFXC1
Biological
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Stanford, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 9, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

NCT04364763
View directory record Official record
Conditions
COVID-19
Interventions
RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 9, 2026, 5:41 AM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

NCT07542314
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

NCT02094716
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Months and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 9, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT03404115
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Waterbury, Connecticut • Indianapolis, Indiana • Lewiston, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 9, 2026, 5:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

NCT07407933
View directory record Official record
Conditions
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Interventions
YL201, Atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Plantation, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 9, 2026, 5:41 AM EDT